Devyani S

8 posts

Devyani S

Devyani S

@DevyaniSurange

Associate consultant Hematology, Heme-Oncology and Bone marrow transplant physician Fortis Memorial Research Institute

Gurugram, Haryana Katılım Eylül 2024
59 Takip Edilen4 Takipçiler
Devyani S retweetledi
Nikhil M Kumar
Nikhil M Kumar@nikhil91sjmc·
Hematologists treat acute leukemias at most centers across the country . Excluding hematologists from clinical trials of “HEMATOLOGICAL MALIGNANCIES “ makes absolutely no sense and is an irony in itself . Really unfortunate that instead of widening access to patients , policy decisions ignore ground realities and come up with such absurd ideas @jayastuMD @royjpalatty @VergheseRenjith @chepsyphilip @TK2K6 @ishbtish @hematologydr @TribikramHemat @TikareNakul @Rohanhematdoc @shanuaswam @RahulDoc2 @dranupjdevasia
Prantar Chakrabarti 3.0@prantar

Has the @CDSCO_INDIA_INF conveniently forgotten that there are #hematologists who are specially trained to treat #bloodcancers ? This order has surprised me as I was a member of the Subject Expert Committee of CDSCO on #HematologyOncology for more than 5 years. If CDSCO feels hematooncologists are not competent to conduct #clinicaltrials on patients with blood cancers then should we stop treating these patients ? @NMC_IND @MoHFW_INDIA @DrPMPGI @RahulDoc2 @drtulikahemat

English
2
7
8
827
Devyani S retweetledi
Prantar Chakrabarti 3.0
Has the @CDSCO_INDIA_INF conveniently forgotten that there are #hematologists who are specially trained to treat #bloodcancers ? This order has surprised me as I was a member of the Subject Expert Committee of CDSCO on #HematologyOncology for more than 5 years. If CDSCO feels hematooncologists are not competent to conduct #clinicaltrials on patients with blood cancers then should we stop treating these patients ? @NMC_IND @MoHFW_INDIA @DrPMPGI @RahulDoc2 @drtulikahemat
Prantar Chakrabarti 3.0 tweet media
English
3
30
22
3.1K
Devyani S
Devyani S@DevyaniSurange·
**6/** Risk stratification here was **MIPSS70+ v2.0: low risk**. Which brings up the more important clinical question: in a “low-risk” patient, do we treat the score, the mutation, or the patient sitting in front of us?
English
0
0
0
19
Devyani S
Devyani S@DevyaniSurange·
**4/** Further workup: **Karyotype: 46,XY** **Myeloid NGS:** * **CALR type 1 mutation** with VAF ~50% * **ZRSR2 mutation** with VAF ~58.5%
0
0
0
30
Devyani S
Devyani S@DevyaniSurange·
**3/** Bone marrow was the real turning point: **markedly hypercellular marrow** with * myeloid hyperplasia * megakaryocytic hyperplasia * dysmegakaryopoiesis * reticulin fibrosis That combination changes the conversation completely.
English
1
0
0
19
Devyani S
Devyani S@DevyaniSurange·
Phenomenal efforts have been put in to make Bhopal cleaner. The efforts are seen. 👏👏👏 @bhopal.
English
0
0
0
28
Devyani S
Devyani S@DevyaniSurange·
@dhruvrahtee For such an act by one individual, you cannot blame the whole system. He should be jailed for sure. But in India people have the freedom to practice their faith, raise their voice, and blame the system. Is this there in any of the Muslim dominated countries?
English
0
0
0
17